Similarly, in a recent study on B-cell lymphoma, BET inhibitors enhanced effective antitumor immunity through regulation of PD-L1, whereas inhibition and genetic ablation of BRD4 resulted in suppression of PD-L1 expression in a transcriptional, Myc-independent, manner. The gene discussed is CD274; the disease is B-cell non-Hodgkin lymphoma.